original_title

Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congr

Source link

What's Hot

Piper Sandler reduz preço-alvo das ações da Lululemon em meio a preocupações com vendas

Baillie Gifford UK Growth Trust busca aprovação para recompra de ações

Take Five: It's TACO time

Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congr

HSBC picks Nelson as interim chair

230%+ gains in the bank: check out our AI’s top picks for June now

Mets vs. Dodgers odds, prediction, props: Proven model’s free 2025 MLB picks, Tuesday, June 3 best bets

MLB insider’s trade deadline picks include Red Sox, Marlins surprises

Queen Elizabeth the Last! Monarchy Faces Fresh Demand to be Axed

Which Airlines are Best Following COVID-19 Safety Protocols

Future Queen of Spain to Attend ‘Finishing School for Royals’

What's Hot

Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congr

Subscribe to Updates